| Literature DB >> 35368942 |
Li Liao1,2, Jiahao Feng3, Xi Fu1, Lifang Cao4, Min Fan2, Cheng Huang2, Jun Zhang5, Lin Zhang5, Peng Chen6, Fengming You1.
Abstract
Background: Hyperplasia of mammary glands (HMG) is the breast disease with the highest clinical incidence. Many traditional Chinese medicine (TCM) doctors suggest that the treatment of HMG should be based on the left and right breast pain difference. However, these views are based on case reports, and an objective basis has not been established for treatment according to left-side and right-side differences.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35368942 PMCID: PMC8967519 DOI: 10.1155/2022/9274060
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Figure 1Tiangui cycle of age distribution in 150 patients (cases). Chi-square (χ2) test; overall comparison of 6 age groups; P < 0.01. Two-seven stage: 14–20 years old; three-seven stage: 21–27 years old; four-seven stage: 28–34 years old; five-seven stage: 35–41 years old; six-seven stage: 42 to 48 years old; seven-seven: 49–55 years old.
Age distribution in patients (x ± s).
| Group | Case (%) | Age (years) |
|---|---|---|
|
| 53 (35.33) | 40.21 ± 9.51 |
|
| 40 (26.67) | 38.27 ± 10.65 |
|
| 57 (38.00) | 40.12 ± 9.68 |
|
| 0.206 | 0.586 |
Chi-square (χ2) test, one-way analysis of variance (ANOVA). L, left; R, right; D, bilateral.
The distribution of breast data (x ± s).
| Group | Case | Breast | Breast pain and lump score (score) | Thickness of breast glands (cm) | ||
|---|---|---|---|---|---|---|
| Left breast | Right breast | Left breast | Right breast | |||
|
| 53 | 104^ | 33.42 ± 6.78 | 18.74 ± 6.78a | 1.20 ± 0.49 | 1.17 ± 0.43 |
|
| 40 | 79 | 17.55 ± 5.06 | 31.57 ± 5.52a | 1.27 ± 0.50 | 1.25 ± 0.52 |
|
| 57 | 114 | 28.37 ± 6.34 | 28.21 ± 5.78 | 1.15 ± 0.35 | 1.16 ± 0.37 |
Comparison of left and right breasts in the same group was performed by the paired T test. aIn the same group, there was a difference between the right breast and the left breast, P < 0.05. ^51 patients had hyperplasia on both sides of the breast, and 2 patients had hyperplasia only on the left side of the breast. There was no pain or mass on the right side of the breast, and no pathological hyperplasia was found by color ultrasound examination.There were 39 patients with bilateral hyperplasia, and 1 patient had hyperplasia of only the right breast, without pain or mass of the left breast, and no pathological hyperplasia was found in the breast color ultrasound examination.
Node detection in three groups.
| Group | Total breast | Breasts with lymph nodes visible | |
|---|---|---|---|
| Left breast | Right breast | ||
|
| 104 | 3.77% (2/53) | 3.92% (2/51) |
|
| 79 | 15.00% (6/40) | 5.13% (2/39) |
|
| 114 | 14.04% (8/57) | 7.02% (4/57) |
|
| — | 0.117# | 0.900# |
#Fisher's exact test.
Distribution of pathological status of patients' breast ducts.
| Group | Total breast | Breasts with ducts dilated | |
|---|---|---|---|
| Left breast | Right breast | ||
|
| 104 | 3.77% (2/53) | 3.92% (2/51) |
|
| 79 | 2.50% (1/40) | 2.56% (1/39) |
|
| 114 | 5.26% (3/57) | 5.26% (3/57) |
|
| — | 0.884# | 0.879# |
#Fisher's exact test.
Figure 2Patient compound constitution and single constitution and detection status.
Figure 3Percent of TCM constitution.
Distribution of TCM constitution types of patients with HMG, n (%).
| TCM constitution |
|
|
|
|
|---|---|---|---|---|
| Balanced | 9 (16.98) | 9 (22.50) | 13 (22.81) | 0.712 |
| Qi-deficient | 25 (47.17) | 9 (22.50) | 21 (36.84) | 0.050 |
| Yang-deficient | 20 (37.74) | 11 (27.50) | 25 (43.86) | 0.260 |
| Yin-deficient | 15 (28.30) | 8 (20.00) | 12 (21.05) | 0.564 |
| Phlegm-dampness | 11 (20.75)b | 28 (70.00)a | 17 (29.82)b | <0.001 |
| Damp-heat | 15 (28.30) | 16 (40.00) | 18 (31.58) | 0.480 |
| Stagnant blood | 43 (81.13)a | 17 (42.50)b | 42 (73.68)a | <0.001 |
| Stagnant qi | 46 (86.79)a | 28 (70.00)b | 43 (75.44)b | 0.002 |
| Inherited special | 4 (7.55) | 1 (2.50) | 5 (8.77) | 0.514# |
#Fisher's exact test. For each indicator, if the overall comparison among the three groups was statistically significant (P < 0.05), further pairwise comparisons were performed. The same letter indicates that the difference is not statistically significant, and the different letters indicate that the difference is statistically significant. Because the patients had complex constitution, the total number of constitution types (511) exceeded the total number of patients (150).
TCM physique scores of patients.
| TCM constitution |
|
|
|
|
|---|---|---|---|---|
| Balanced | 56.00 (41.00; 75.00) | 69.00 (53.00; 72.75) | 63.00 (50.00; 72.00) | 0.311 |
| Qi-deficient | 25.00 (16.00; 38.00) | 22.00 (15.25; 28.75) | 22.00 (16.00; 38.00) | 0.414 |
| Yang-deficient | 25.00 (11.00; 43.00) | 18.00 [11.00; 33.00] | 25.00 (11.00; 43.00) | 0.322 |
| Yin-deficient | 22.00 (13.00; 31.00) | 14.50 (9.00; 25.00) | 19.00 (9.00; 28.00) | 0.490 |
| Phlegm-dampness | 22.00 (13.00; 28.00)b | 39.50 (25.00; 44.75)a | 22.00 (16.00; 34.00)b | <0.001 |
| Damp-heat | 21.00 (8.00; 33.00) | 25.00 (13.00; 38.00) | 25.00 (13.00; 33.00) | 0.299 |
| Stagnant blood | 41.74 ± 14.22a | 29.40 ± 16.07b | 40.86 ± 15.29a | <0.001 |
| Stagnant Qi | 46.06 ± 14.60a | 37.77 ± 16.58b | 40.72 ± 15.68b | 0.034 |
| Inherited special | 7.00 (0.00; 21.00) | 5.50 (0.00; 14.00) | 7.00 (0.00; 18.00) | 0.548 |
#Fisher's exact test. For each indicator, if the overall comparison among the three groups was statistically significant (P < 0.05), further pairwise comparisons were performed. The same letter indicates that the difference is not statistically significant, and the different letters indicate that the difference is statistically significant.
HMG patient blood indicators.
| Biochemical indicators |
|
|
|
| |
|---|---|---|---|---|---|
| ( | ( | ( | |||
| Routine blood test | WBC (109/L) | 5.53 (4.97; 6.57) | 6.02 (4.84; 7.49) | 5.58 (4.74; 6.84) | 0.741 |
| RBC (1012/L) | 4.40 ± 0.50 | 4.35 ± 0.49 | 4.22 ± 0.43 | 0.171 | |
| HB (g/L) | 130.00 (123.00; 138.00) | 129.00 (120.00; 134.75) | 128.50 (120.50; 133.75) | 0.854 | |
| PLT (109/L) | 210.00 (190.00; 251.00) | 219.00 (185.00; 254.00) | 209.50 (180.00; 261.75) | 0.932 | |
| NEUT (109/L) | 66.64 ± 11.59 | 61.53 ± 11.91 | 65.20 ± 7.96 | 0.116 | |
| LYM (109/L) | 25.07 ± 9.65 | 29.30 ± 10.28 | 25.60 ± 8.05 | 0.126 | |
| MONO (109/L) | 5.86 ± 2.00 | 6.53 ± 2.15 | 6.38 ± 1.42 | 0.248 | |
| EO (109/L) | 1.30 (0.70; 2.70) | 1.45 (0.83; 1.98) | 1.30 (0.70; 2.38) | 0.973 | |
| BASO (109/L) | 0.50 (0.40; 0.60) | 0.50 (0.32; 0.70) | 0.40 (0.30; 0.60) | 0.813 | |
| HCT (%) | 39.70 (37.20; 41.90) | 40.05 (36.92; 41.58) | 39.55 (37.28; 41.27) | 0.752 | |
| Routine coagulation tests | PT (s) | 10.60 (10.20; 10.80) | 10.60 (10.10; 10.90) | 10.50 (10.20; 10.95) | 0.924 |
| APTT (s) | 25.20 (23.20; 27.70) | 26.15 (25.13; 27.32) | 25.90 (24.00; 27.50) | 0.442 | |
| Fib (g/L) | 2.76 (2.44; 3.24) | 2.83 (2.40; 3.33) | 2.53 (2.21; 3.52) | 0.752 | |
| TT (s) | 17.35 ± 1.15 | 17.22 ± 1.20 | 17.77 ± 0.96 | 0.059 | |
| FVIII (IU/dL) | 155.90 (114.80; 177.00)a | 115.05(95.33; 134.20)c | 132.00 (112.10; 155.15)b | 0.001 | |
| Renal function tests | Urea (mmol/L) | 4.44 ± 1.26 | 4.45 ± 1.20 | 4.62 ± 1.35 | 0.757 |
| SCr (umol/L) | 59.00 (50.00; 62.00)a | 53.60 (49.38; 56.75)b | 59.00 (54.00; 64.50)a | 0.02 | |
| URIC (umol/L) | 236.00 (209.00; 280.00)b | 251.50 (209.75; 292.75)ab | 274.00 (237.25; 310.25)a | 0.04 | |
| Cys C (mg/L) | 0.84 (0.80; 0.88)a | 0.78 (0.74; 0.84)b | 0.86 (0.79; 0.94)a | 0.023 | |
|
| 1.31 (1.23; 1.58)ab | 1.21 (1.12; 1.36)b | 1.42 (1.26; 1.61)a | 0.022 | |
| Blood lipids tests | TG (mmol/L) | 1.18 (0.82; 1.51) | 1.35 (0.92; 1.58) | 1.17 (0.85; 1.76) | 0.905 |
| TC (mmol/L) | 4.19 ± 0.68 | 4.68 ± 1.06 | 4.40 ± 1.04 | 0.105 | |
| HDL (mmol/L) | 1.42 (1.12; 1.70) | 1.64 (1.39; 1.84) | 1.50 (1.24; 1.73) | 0.196 | |
| LDL (mmol/L) | 2.63 ± 0.67 | 3.05 ± 1.05 | 2.83 ± 0.91 | 0.140 | |
| APOA1 (g/L) | 1.45 ± 0.21 | 1.56 ± 0.23 | 1.52 ± 0.25 | 0.134 | |
| APOB (g/L) | 0.82 ± 0.20 | 0.93 ± 0.31 | 0.87 ± 0.25 | 0.210 | |
| Lp- | 18.00 (5.00; 50.40)b | 57.75 (8.27; 127.25)a | 11.50 (7.20; 37.50)b | 0.032 | |
| Liver function tests | TP (g/L) | 75.20 ± 5.81 | 75.20 ± 5.87 | 73.89 ± 4.74 | 0.427 |
| ALB (g/L) | 47.09 ± 4.11 | 47.58 ± 3.78 | 45.92 ± 3.14 | 0.111 | |
| GLB (g/L) | 28.40 (25.60; 30.60) | 26.85 (25.23; 29.60) | 28.00 (26.42; 30.28) | 0.626 | |
| A/ | 1.70 ± 0.24 | 1.75 ± 0.26 | 1.67 ± 0.25 | 0.351 | |
| ALT (U/L) | 13.20 (10.40; 16.20) | 15.85 (12.27; 20.15) | 14.50 (11.53; 19.77) | 0.066 | |
| AST (U/L) | 17.40 (14.70; 19.90) | 18.55 (14.90; 22.92) | 19.20 (15.95; 23.20) | 0.165 | |
| AST/ALT | 1.29 (1.07; 1.62) | 1.19 (0.90; 1.43) | 1.22 (1.04; 1.47) | 0.315 | |
| TBIL (umol/L) | 8.90 (7.30; 12.50) | 9.60 (6.58; 11.80) | 8.35 (6.23; 12.47) | 0.753 | |
| DBIL (umol/L) | 3.50 (2.90; 4.70) | 3.55 (3.02; 4.65) | 3.40 (2.62; 4.47) | 0.703 |
One-way analysis of variance (ANOVA), Kruskal–Wallis H test. For each indicator, if the overall comparison among the three groups was statistically significant (P < 0.05), further pairwise comparisons were performed. The same letter indicates that the difference is not statistically significant, and the different letters indicate that the difference is statistically significant.
Figure 4KEGG enrichment analysis of herbal targets (a) Qingpi in KEGG enrichment analysis; (b) Chenpi in KEGG enrichment analysis. The abscissa represents the degree of association between the pathway and the target, the ordinate represents the name of the pathway, the size of the dot represents the number of genes, and the color represents the P value.